NM_000245.4:c.1200+1942G>A

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP4_ModerateBA1

The NM_000245.4(MET):​c.1200+1942G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0617 in 152,106 control chromosomes in the GnomAD database, including 383 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.062 ( 383 hom., cov: 32)

Consequence

MET
NM_000245.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 0.860

Publications

5 publications found
Variant links:
Genes affected
MET (HGNC:7029): (MET proto-oncogene, receptor tyrosine kinase) This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
COMETT (HGNC:51196): (cytosolic oncogenic antisense to MET transcript) This gene encodes a natural antisense transcript highly expressed in papillary thyroid carcinomas harboring BRAF V600E mutation or RET gene rearrangements. This lncRNA induces the downstream MAPK pathway and is part of a co-expression network including different oncogenes belonging to the MAPK and PI3H/AKT pathways. In thyroid carcinomas, this gene has oncogenic properties associated with increased proliferation and drug resistance. [provided by RefSeq, Jan 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.37).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.103 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
METNM_000245.4 linkc.1200+1942G>A intron_variant Intron 2 of 20 ENST00000397752.8 NP_000236.2 P08581-1A0A024R759

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
METENST00000397752.8 linkc.1200+1942G>A intron_variant Intron 2 of 20 1 NM_000245.4 ENSP00000380860.3 P08581-1

Frequencies

GnomAD3 genomes
AF:
0.0615
AC:
9348
AN:
151988
Hom.:
376
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.105
Gnomad AMI
AF:
0.0515
Gnomad AMR
AF:
0.0808
Gnomad ASJ
AF:
0.0251
Gnomad EAS
AF:
0.0699
Gnomad SAS
AF:
0.0442
Gnomad FIN
AF:
0.00944
Gnomad MID
AF:
0.0696
Gnomad NFE
AF:
0.0416
Gnomad OTH
AF:
0.0526
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.0617
AC:
9386
AN:
152106
Hom.:
383
Cov.:
32
AF XY:
0.0607
AC XY:
4513
AN XY:
74360
show subpopulations
African (AFR)
AF:
0.105
AC:
4374
AN:
41488
American (AMR)
AF:
0.0806
AC:
1230
AN:
15258
Ashkenazi Jewish (ASJ)
AF:
0.0251
AC:
87
AN:
3472
East Asian (EAS)
AF:
0.0701
AC:
363
AN:
5178
South Asian (SAS)
AF:
0.0444
AC:
214
AN:
4818
European-Finnish (FIN)
AF:
0.00944
AC:
100
AN:
10594
Middle Eastern (MID)
AF:
0.0782
AC:
23
AN:
294
European-Non Finnish (NFE)
AF:
0.0416
AC:
2829
AN:
67978
Other (OTH)
AF:
0.0563
AC:
119
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
443
886
1329
1772
2215
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
108
216
324
432
540
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0525
Hom.:
318
Bravo
AF:
0.0679
Asia WGS
AF:
0.0740
AC:
259
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.37
CADD
Benign
15
DANN
Benign
0.81
PhyloP100
0.86
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17138943; hg19: chr7-116342280; API